Literature DB >> 11038151

Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures.

R Venkataramanan1, V Ramachandran, B J Komoroski, S Zhang, P L Schiff, S C Strom.   

Abstract

Milk thistle extract is one of the most commonly used nontraditional therapies, particularly in Germany. Milk thistle is known to contain a number of flavonolignans. We evaluated the effect of silymarin, on the activity of various hepatic drug-metabolizing enzymes in human hepatocyte cultures. Treatment with silymarin (0.1 and 0.25 mM) significantly reduced the activity of CYP3A4 enzyme (by 50 and 100%, respectively) as determined by the formation of 6-beta-hydroxy testosterone and the activity of uridine diphosphoglucuronosyl transferase (UGT1A6/9) (by 65 and 100%, respectively) as measured by the formation of 4-methylumbelliferone glucuronide. Silymarin (0.5 mM) also significantly decreased mitochondrial respiration as determined by MTT reduction in human hepatocytes. These observations point to the potential of silymarin to impair hepatic metabolism of certain coadministered drugs in humans. Indiscriminate use of herbal products may lead to altered pharmacokinetics of certain drugs and may result in increased toxicity of certain drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038151

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  32 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Effects of long-term silymarin oral supplementation on the blood biochemical profile of rainbow trout (Oncorhynchus mykiss).

Authors:  Mahdi Banaee; Antoni Sureda; Ali Reza Mirvaghefi; Golam Reza Rafei
Journal:  Fish Physiol Biochem       Date:  2011-04-26       Impact factor: 2.794

Review 3.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

4.  Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Authors:  Bill Gurley; Martha A Hubbard; D Keith Williams; John Thaden; Yudong Tong; W Brooks Gentry; Philip Breen; Danielle J Carrier; Shreekar Cheboyina
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

5.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

6.  The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.

Authors:  Marina Kawaguchi-Suzuki; Reginald F Frye; Hao-Jie Zhu; Bryan J Brinda; Kenneth D Chavin; Hilary J Bernstein; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2014-07-15       Impact factor: 3.922

7.  An unwanted complement: Rare case of potential liver injury induced by an interaction between ginseng and atorvastatin.

Authors:  Robyn Laube; Ken Liu
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

8.  Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.

Authors:  José Moltó; Marta Valle; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 9.  Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements.

Authors:  Alyssa A Sprouse; Richard B van Breemen
Journal:  Drug Metab Dispos       Date:  2015-10-05       Impact factor: 3.922

10.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.